Book Excerpt from The Politics of Cancer

In Chapter 2, “Identifying the Culprits,” author Wendy Whitman Cobb describes how small-government, anti-regulation conservatism can hinder the fight against cancer.

Written byWendy N. Whitman Cobb
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

PRAEGER, MARCH 2017It’s hard to believe that something like cancer, which doesn’t care about your party affiliation, could have a partisan tinge to it. And yet Proctor, in his book Cancer Wars, argues that politics itself has been an integral factor in cancer funding and prevention efforts. His history suggests that ideologically influenced administrations, including those of the Carter and Reagan presidencies, had significant effects on cancer prevention and funding. Consistent with the overall regulatory cuts suffered under the Reagan administration, Proctor details how environmental prevention efforts in the form of Occupational Safety and Health Administration (OSHA) and Environmental Protection Agency (EPA) regulations were dramatically scaled back from Carter-era levels.

This work suggests that although politicians of all stripes may in principle support the idea of curing cancer or supporting cancer research, there are embedded issues in cancer policy that lend themselves to party politics. These elements include budgetary and regulatory politics, as well as general attitudes toward science policies. To begin with general attitudes toward science, again, it does not instantly strike many of us that supporting science would be a political football to be tossed about. And yet, Democrats and Republicans have strikingly different attitudes not only about science, but also about different types of science. For example, space policy, decisions about whether and when to send humans into outer space, has been shown to be a Republican issue. Why would space be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies